Latest immunotherapy News | Page 2

Analysis of brain tumor blood vessels yields a candidate therapy-and a platform to find more
Revolutionizing Drug Development: Novigenix Unveils AI-Powered RNA Analysis for Immune Response Profiling
Combo treatment improves lung cancer outcomes
Young teacher shares his cancer story to educate students about sun safety
New therapy will revolutionise treatment of urothelial and bladder cancers
Works underway on Royal Hobart Hospital Pharmacy Redevelopment Project
Bright ideas attract major funding
New treatment for deadly uterine cancer
DFG Funding for Immunology Research in Würzburg
Monica’s message about skin cancer: It doesn’t discriminate, I wish more people would Slip, Slop, Slap
Cheaper medicines for breast cancer, small cell lung cancer, biliary tract cancer, juvenile idiopathic arthritis and Crohn’s disease
Dr Ben Wylie research to develop kinder and less toxic treatments for cancer
Nutrient in beef and dairy products boosts immune response to cancer
Weill Cornell Medicine to open medical research center
New therapy target to shut down multiple myeloma’s ability to survive and thrive
EnGeneIC’s breakthrough Armed Nanocell Drug Conjugate (ANDC) treatment shows promising results in Pancreatic cancer patients who have run out of treatment options
Drug resistance may make common infections like thrush untreatable
$50 million boost to research for health problems
Unlocking power of immune system to kill prostate cancer
HaemaLogiX Announces Appointment of Damian Clarke-Bruce as Managing Director and CEO
New culprit in amyloid beta buildup, neurodegeneration
Leukaemia Foundation and HSANZ funding next generation of clinicians and researchers to save more Australian lives
Preventing Exhaustion of T Cells
Multi-million dollar boost into child research programs
Dom’s Finding strength in being open about cancer
Cancer’s sweet Achilles heel
Clinical trials give Queensland breast cancer patients hope
Positive efficacy result for Immutep’s ‘efti’ in combination with MSD’s pembrolizumab
Enhertu approved in the EU as the first HER2-directed therapy for patients with HER2-mutant advanced non-small cell lung cancer
Datopotamab deruxtecan plus Imfinzi demonstrated robust and durable tumour responses in 1st-line treatment of patients with metastatic triple-negative breast cancer in BEGONIA…
Imfinzi plus chemotherapy more than doubled pathologic complete response rate in resectable early-stage gastric and gastroesophageal junction cancers versus chemotherapy alone
Alice Springs Hospital oncology and cardiology services supporting patients
Western Australian doctors to explore new frontiers in cancer fight
Research Advisory Board Welcomes Professor Cameron Turtle
Ludwig Institute Board Member Jedd Wolchok elected to National Academy of Medicine
New approaches to blood and liver cancer therapies recognised with $2.5 million CSL Centenary Fellowships
AstraZeneca advances scientific leadership across multiple cancers with first data from four pivotal Phase III trials at ESMO
Fall allergies: Ragweed and mold are in air
Study shows how brain tumors make certain immune cells turn traitor
Combination therapy promising against ‘cold’ breast cancer tumors
Combination of personalized cancer vaccine and adoptive T cell therapy benefits patients with advanced ovarian cancer
Disrupting a core metabolic process in T cells may improve their therapeutic efficacy
How do hay fever treatments actually work? And what’s best for my symptoms?
£½ million funding announced to find new treatment for oesophageal cancer
Enhertu recommended for approval in the EU by CHMP for patients with HER2-mutant advanced non-small cell lung cancer
Imugene secures new patent in Japan for PD1-Vaxx clinical drug candidate
Veronica’s Finding light beyond storm
BCNA welcomes decision to recommend Keytruda for subsidy for early-stage breast cancer